83004-14-2

Basic information

• Product Name: 2-Bromo-4-bromomethyl-pyridine
• Synonyms: 2-Bromo-4-bromomethyl-pyridine;2-Bromo-4-(bromomethyl)
• CAS NO: 83004-14-2
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 251
• Mol File: 83004-14-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 298.8°C at 760 mmHg
• Flash Point: 134.5°C
• Appearance: /
• Density: 1.955
• Vapor Pressure: 0.0022mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.38±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-4-bromomethyl-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-bromomethyl-pyridine(83004-14-2)
• EPA Substance Registry System: 2-Bromo-4-bromomethyl-pyridine(83004-14-2)

Safety Data

• Hazardous Substances Data: 83004-14-2(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-bromomethyl-pyridine is a chemical compound with the molecular formula C6H5Br2N. It is a brominated derivative of pyridine, which is a heterocyclic compound commonly found in various natural products and pharmaceuticals. 2-Bromo-4-bromomethyl-pyridine is used in organic synthesis and medicinal chemistry as a building block for creating diverse compounds with potential biological activity. Its unique brominated structure makes it a valuable precursor for producing complex molecules with specific pharmaceutical properties. Additionally, it is employed in the development of agrochemicals, dyes, and other industrial products. Due to its potential reactivity and toxicity, proper handling and safety precautions are necessary when working with 2-Bromo-4-bromomethyl-pyridine.

InChI:InChI=1/C6H5Br2N/c7-4-5-1-2-9-6(8)3-5/h1-3H,4H2

Upstream product

• 4926-28-7 2-Bromo-4-picoline 
• 34241-39-9 azobisisobutyronitrile 
• 695-34-1 2-Amino-4-methylpyridine 
• 118289-16-0 (2-bromopyridin-4-yl)methanol 
• 118289-17-1 2-bromopyridine-4-carboxaldehyde 

Downstream Products

• 88443-57-6 2-bromo-4-dimethylaminomethylpyridine 
• 193001-88-6 7-((2-chloro-pyridin-4-yl)methoxy)-6-methoxy-4-phenoxyquinazoline 

Relevant articles and documents

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

The chemokine receptor CXCR4/stromal cell-derived factor-1 (SDF-1: CXCL12) signaling axis represents a crucial drug target due to its relevance to several diseases such as HIV-1 infection, cancer, leukemia, and rheumatoid arthritis. With the aim of enhancing the binding affinity and anti-HIV activity of a potent CXCR4 ligand as a lead, 23 low molecular weight compounds containing dipicolylamine (Dpa) and cyclam cationic moieties with varying spacers and spatial positioning were designed, synthesized and biologically evaluated. All of the synthesized compounds screened at 1.0 μM in the NanoBRET assay system exhibited >70% inhibition of the binding of a competitive probe TAMRA-Ac-TZ14011 (10 nM) to CXCR4 in the presence of zinc (II) ion. Furthermore, selected compounds 3, 8, 9, 19 and 21 with spatial distances between the next carbon to Dpa and the next carbon to cyclam within the range of 6.5–7.5 ? showed potent binding affinity selective for CXCR4 with IC50 values of 1.6, 7.9, 5.7, 3.5 and 4.5 nM, respectively, with corresponding high anti-HIV activity with EC50s of 28, 13, 21, 28 and 61 nM, respectively, in the presence of zinc (II) ion. Some compounds with remarkably more potent CXCR4-binding affinity than that of an initial lead were obtained. These compounds interact with different but overlapping amino acid residues of CXCR4. The present studies have developed new low molecular weight CXCR4 ligands with high CXCR4-binding and anti-HIV activities, which open avenue into the development of more potent CXCR4 ligands.

HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS

The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention

HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS

The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.